Title:
The IPP complex as a marker for Erlotinib medical treatment
Document Type and Number:
Japanese Patent JP6096664
Kind Code:
B2
Abstract:
The present invention provides biomarkers which are predictive for the clinical benefit of erlotinib hydrochloride treatment in cancer patients.
More Like This:
Inventors:
Augustin, Angelique
Du Chateau-Nguyen, Guimet
Escue, Laurent
Goring, sabrina
Crew hammer, Barbara
Ramelz, Jens
Langen, Hanno
Meisterman, Elaine
Scheibrich, Stephan
Manuel
Du Chateau-Nguyen, Guimet
Escue, Laurent
Goring, sabrina
Crew hammer, Barbara
Ramelz, Jens
Langen, Hanno
Meisterman, Elaine
Scheibrich, Stephan
Manuel
Application Number:
JP2013533193A
Publication Date:
March 15, 2017
Filing Date:
October 12, 2011
Export Citation:
Assignee:
Ef Hoffman-La Roche Akchengezel Shaft
International Classes:
G01N33/68; A61K31/517; A61P35/00; C07D239/94; C12Q1/68; G01N33/50; G01N37/00
Domestic Patent References:
| JP2008533490A |
Other References:
B C FUCHS,EPITHELIAL-TO-MESENCHYMAL TRANSITION AND INTEGRIN-LINKED KINASE MEDIATE SENSITIVITY TO EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITION IN HUMAN HEPATOMA CELLS,CANCER RESEARCH,2008年 4月 1日,V68 N7,P2391-2399
E -H TAN,A MULTICENTRE PHASE II GENE EXPRESSION PROFILING STUDY OF PUTATIVE RELATIONSHIPS BETWEEN TUMOUR BIOMARKERS AND CLINICAL RESPONSE WITH ERLOTINIB IN NON-SMALL-CELL LUNG CANCER,ANNALS OF ONCOLOGY,2010年 2月 1日,V21 N2,P217-222
Elizabeth R. Abboud et al.,Integrin-linked kinase: A hypoxia-induced anti-apoptotic factor exploited by cancer cells,International Journal of Oncology,2007年,Vol. 30,113-122
Kyle R. Legate et al.,ILK, PINCH and parvin: the tIPP of integrin signalling,Nature Reviews Molecular Cell Biology,2006年 1月,7,20-31
THOMSON S,EPITHELIAL TO MESENCHYMAL TRANSITION IS A DETERMINANT OF SENSITIVITY OF NON-SMALL-CELL LUNG CARCINOMA CELL LINES AND XENOGRAFTS TO EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITION,CANCER RESEARCH,米国,AMERICAN ASSOCIATION FOR CANCER RESEARCH,2005年10月15日,V65 N20,P9455-9462
HEINTZ,Asbestos, Lung Cancers, and Mesotheliomas From Molecular Approaches to Targeting Tumor Survival Pathways,Am J Respir Cell Mol Biol,2010年,Vol.42 No.2,Page.133-139
E -H TAN,A MULTICENTRE PHASE II GENE EXPRESSION PROFILING STUDY OF PUTATIVE RELATIONSHIPS BETWEEN TUMOUR BIOMARKERS AND CLINICAL RESPONSE WITH ERLOTINIB IN NON-SMALL-CELL LUNG CANCER,ANNALS OF ONCOLOGY,2010年 2月 1日,V21 N2,P217-222
Elizabeth R. Abboud et al.,Integrin-linked kinase: A hypoxia-induced anti-apoptotic factor exploited by cancer cells,International Journal of Oncology,2007年,Vol. 30,113-122
Kyle R. Legate et al.,ILK, PINCH and parvin: the tIPP of integrin signalling,Nature Reviews Molecular Cell Biology,2006年 1月,7,20-31
THOMSON S,EPITHELIAL TO MESENCHYMAL TRANSITION IS A DETERMINANT OF SENSITIVITY OF NON-SMALL-CELL LUNG CARCINOMA CELL LINES AND XENOGRAFTS TO EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITION,CANCER RESEARCH,米国,AMERICAN ASSOCIATION FOR CANCER RESEARCH,2005年10月15日,V65 N20,P9455-9462
HEINTZ,Asbestos, Lung Cancers, and Mesotheliomas From Molecular Approaches to Targeting Tumor Survival Pathways,Am J Respir Cell Mol Biol,2010年,Vol.42 No.2,Page.133-139
Attorney, Agent or Firm:
Sonoda/Kobayashi Patent Business Corporation
Previous Patent: The composite material roller for high temperature Annealing
Next Patent: PRODUCTION OF WATER-SOLUBLE, METAL COATING CLEAR LACQUER
Next Patent: PRODUCTION OF WATER-SOLUBLE, METAL COATING CLEAR LACQUER